Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

Bookmark and Share
Published: 9 Oct 2016
Views: 1499
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Dr Reck presents, at a press conference at ESMO 2016, results from the KEYNOTE-024 trial which he believes recommend the use of PD1 antibody pembrolizumab as first-line therapy for patients with NSCLC whose tumours express high levels of PDL-1.

These results complement those presented by Dr Langer, who reports improved outcomes for NSCLC patients receiving firstline pembrolizumab and chemotherapy.

Dr Reck spoke more about these results with ecancer here